Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study
Kristina Charaya, Dmitry Shchekochikhin, Д. А. Андреев, et al.
Open Heart (2022) Vol. 9, Iss. 1, pp. e001936-e001936
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Cardiovascular and renal effects of SGLT2 inhibitor initiation in acute heart failure: a meta-analysis of randomized controlled trials
Pedro E.P. Carvalho, Thiago M. A. Veiga, Ana Cristina Simões e Silva, et al.
Clinical Research in Cardiology (2023) Vol. 112, Iss. 8, pp. 1044-1055
Open Access | Times Cited: 29
The Role of Sodium-Glucose Co-Transporter-2 Inhibitors on Diuretic Resistance in Heart Failure
Panagiotis Stachteas, Athina Nasoufidou, Dimitrios Patoulias, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3122-3122
Open Access | Times Cited: 14
Safety and efficacy of early initiation of sodium-glucose co-transporter inhibitors 2 in patients hospitalized for acute heart failure: A meta-analysis of randomized controlled trials
Renzo Laborante, Donato Antonio Paglianiti, Emiliano Bianchini, et al.
European Journal of Internal Medicine (2025)
Open Access | Times Cited: 1
Randomized trial to assess worsening renal function by adding dapagliflozin for acute decompensated heart failure
Shodai Kawanami, Yasuyuki Egami, Masaru Abe, et al.
ESC Heart Failure (2025)
Open Access | Times Cited: 1
Impact of Dapagliflozin Treatment on Serum Sodium Concentrations in Acute Heart Failure
Kristina Charaya, Dmitry Shchekochikhin, A. A. Agadzhanyan, et al.
Cardiorenal Medicine (2023), pp. 101-108
Open Access | Times Cited: 11
Have SGLT-2 inhibitors DELIVERed an EMPhatic win in heart failure and chronic kidney disease?
Awadhesh Kumar Singh, Akriti Singh, Ritu Singh
Expert Opinion on Pharmacotherapy (2025)
Closed Access
Efficacy and safety of SGLT2 inhibitors in acute heart failure: a systematic review and meta-analysis of randomized controlled trials
Ali Rahil, Tapan Bhavsar, Rida Fatima, et al.
Frontiers in Cardiovascular Medicine (2025) Vol. 12
Open Access
Redefining treatment paradigms: Early use of dapagliflozin and empagliflozin in acute heart failure – a systematic review and meta-analysis of randomized controlled trials
Surya S. Immanuel, Eric Ricardo Yonatan, Gabriel Tandecxi, et al.
Narra J (2025) Vol. 5, Iss. 1, pp. e1833-e1833
Open Access
The impact of sodium-glucose co-transporter-2 inhibitors on serum sodium and potassium in patients with Heart Failure: a systematic review and meta-analysis
Reza Amani‐Beni, Bahar Darouei, Davood Shafie, et al.
BMC Cardiovascular Disorders (2025) Vol. 25, Iss. 1
Open Access
Early Initiation of Sodium–Glucose Cotransporter 2 Inhibitors in Acute Heart Failure: A Systematic Review and Meta‐Analysis
Miloud Cherbi, Olivier Lairez, Guillaume Baudry, et al.
Journal of the American Heart Association (2025)
Open Access
The Therapeutic Role of SGLT-2 Inhibitors in Acute Heart Failure: From Pathophysiologic Mechanisms to Clinical Evidence with Pooled Analysis of Relevant Studies across Safety and Efficacy Endpoints of Interest
Dimitrios Patoulias, Nikolaos Fragakis, Manfredi Rizzo
Life (2022) Vol. 12, Iss. 12, pp. 2062-2062
Open Access | Times Cited: 15
Efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with acute heart failure: a systematic review and meta-analysis
Jingjin Hou, Li Ren, Qingbin Hou, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 2
Dapagliflozin in acute heart failure management: a systematic review and meta-analysis of safety and effectiveness
Adarsh Raja, Mata‐e‐Alla Dogar, Sandesh Raja, et al.
BMC Cardiovascular Disorders (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Cardiovascular outcomes in patients treated with sodium-glucose transport protein 2 inhibitors, a network meta-analysis of randomized trials
Dániel Tornyos, Maximilian Meuer, Réka Lukács, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 9
Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin
Carlos Escobar Cervantes, Domingo A. Pascual‐Figal, Luís Manzano, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 21, pp. 6798-6798
Open Access | Times Cited: 5
La reducción temprana del filtrado glomerular se asocia con aumento de la hemoglobina tras el inicio de dapagliflozina en la insuficiencia cardiaca con fracción de eyección reducida
Gema Miñana, Rafael de la Espriella, Patricia Palau, et al.
Revista Española de Cardiología (2023) Vol. 76, Iss. 10, pp. 783-792
Closed Access | Times Cited: 2
In-hospital results of therapy with the NGLT-2 inhibitor dapagliflozin in patients with acute decompensation of heart failure: prospective randomized study
О. М. Омаров, G. G. Arabidze, Zaur Shogenov, et al.
Cardiosomatics (2024) Vol. 15, Iss. 1, pp. 31-40
Open Access
Efecto terapéutico de los inhibidores del cotransportador sodio-glucosa tipo 2 en la insuficiencia cardiaca aguda
Jonathan Navarro-Solano, Chih Hao Chen-Ku
Acta Médica Costarricense (2024) Vol. 65, Iss. 4, pp. 1-8
Open Access
Update on evidence-based clinical application of sodium-glucose cotransporter inhibitors: Insight to uncommon cardiovascular disease scenarios in diabetes
Shibing Tao, Xi Lu, Zi‐Wei Ye, et al.
World Journal of Diabetes (2024) Vol. 15, Iss. 7, pp. 1461-1476
Open Access
Effect of dapagliflozin on readmission and loop diuretics use in patients with acute heart failure: a retrospective propensity score-matched cohort study
Dong Wu, Zhen Ma, Xiaoying Wang, et al.
BMC Cardiovascular Disorders (2024) Vol. 24, Iss. 1
Open Access
EARLY RESULTS OF THE THERAPY WITH THE NGLT-2 INHIBITOR DAPAGLIFLOZIN IN PATIENTS WITH ACUTE DECOMPENSATION OF HEART FAILURE
G. G. Arabidze, О. М. Омаров, Zaur Shogenov, et al.
Медицинский вестник МВД (2024) Vol. 2024, Iss. 4, pp. 57-61
Closed Access
In-hospital diuretic resistance as a risk factor for poor long-term prognosis in chronic heart failure
O.P. Bilaya, A. A. Nartov, Kristina Charaya, et al.
Russian Journal of Cardiology and Cardiovascular Surgery (2024) Vol. 17, Iss. 5, pp. 532-532
Closed Access
SGLT-2 inhibitors in the management of acute decompensated heart failure
Anastasiya E. Poskakalova, S. N. Nasonova, И. В. Жиров, et al.
Consilium Medicum (2024) Vol. 26, Iss. 10, pp. 649-655
Open Access
A systematic review and meta-analysis assessing the safety and efficacy of sodium-glucose co-transporter 2 inhibitor use in hospitalized patients
Feng Gao, Aleena S. Ali, Rinaldo Bellomo, et al.
(2024)
Open Access
Early glomerular filtration rate decline is associated with hemoglobin rise following dapagliflozin initiation in heart failure with reduced ejection fraction
Gema Miñana, Rafael de la Espriella, Patricia Palau, et al.
Revista Española de Cardiología (English Edition) (2023) Vol. 76, Iss. 10, pp. 783-792
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top